2026 · 2nd Quarter (Apr 1 - June 30)

AMGEN, INC.

Filed by WILLIAMS AND JENSEN, PLLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: WILLIAMS AND JENSEN, PLLC
Client: AMGEN, INC.
Filing UUID: e1fe02d7-96d5-4c9e-8307-6da5f4e3c646
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Policies impacting disease prevention.

LBR · Labor Issues/Antitrust/Workplace

Issues related to antitrust legislation.

CPT · Copyright/Patent/Trademark

Issues related to patent protections.

HCR · Health Issues

General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals.

MMM · Medicare/Medicaid

Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars.

Literal federal measure citations: H.R. 1

TAX · Taxation/Internal Revenue Code

Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.